GTC adds partnerships and pathology leaders as precision oncology business expands

Genomic Testing Cooperative said Tuesday it hired Sonia Gill as head of partnerships and Anthony Wheeler, MD, as a hematopathologist as the Lake Forest, California, molecular diagnostics company scales its precision oncology platform. The moves are meant to widen commercial reach while adding clinical expertise for clinicians, laboratories and strategic partners.

Why it matters: - Genomic Testing Cooperative is pairing commercial growth with added scientific depth as demand rises for advanced molecular testing in precision oncology. - The new hires are designed to strengthen client support, expand partnerships and improve genomic interpretation for cancer care. - The additions also signal GTC’s push to broaden access to DNA and RNA profiling for solid and hematologic malignancies.

What happened: - GTC announced two leadership additions: Sonia Gill joined as head of partnerships, and Anthony Wheeler, MD, joined as a hematopathologist. - The company said the appointments are part of its effort to expand capabilities, market presence and support for clinicians and laboratory partners. - GTC founder and CEO Maher Albitar said the company needs to grow its market presence and scientific capabilities at the same time.

The details: - Gill will lead business development efforts aimed at clinicians, health systems, laboratories and strategic partners. - Gill previously held commercial leadership roles at Baylor Genetics, Sema4, NeoGenomics Laboratories and Genoptix. - GTC said Gill will help broaden awareness and adoption of its molecular testing portfolio. - Wheeler is board certified in anatomic and clinical pathology. - Wheeler completed his pathology residency at Loyola University Medical Center. - Wheeler completed his hematopathology fellowship at the University of California, Irvine. - Wheeler has training across biomedical engineering, diagnostic medicine, molecular diagnostics, laboratory science, diagnostic instrumentation and quality systems. - At GTC, Wheeler will work with other pathologists to interpret and clinically apply genomic testing. - GTC said the expanded team gives clients broader access to expertise and more clinical support behind its testing services. - GTC operates as a next-generation sequencing laboratory under a cooperative model. - The company offers comprehensive DNA and RNA profiling for solid and hematologic malignancies, including liquid and CSF biopsies. - GTC says its mission is to democratize access to advanced genomics and support innovation in precision oncology. - More information - GTC also listed its LinkedIn page: Genomic Testing Cooperative on LinkedIn

Between the lines: - The hires combine business development with pathology expertise, suggesting GTC wants to convert scientific capability into broader market adoption. - The company is emphasizing both clinical rigor and commercial infrastructure as competition intensifies in molecular diagnostics. - Albitar framed the strategy as one where scientific innovation, clinical interpretation and market access reinforce one another.

What's next: - GTC is likely to use the new leadership to deepen relationships with clinicians, laboratories and strategic partners. - The company said it will continue expanding its market presence and supporting clinicians with genomic testing and clinical interpretation. - GTC also said it will keep investing in the scientific and clinical support behind its testing services.

The bottom line: - GTC is building out both the sales and science sides of its precision oncology platform to support growth and wider adoption.